Konturek P C, Bobrzynski A, Konturek S J, Bielanski W, Faller G, Kirchner T, Hahn E G
Dept. of Medicine I and Institute of Pathology, University of Erlangen-Nuremburg, Erlangen, Germany.
Scand J Gastroenterol. 1998 Feb;33(2):143-51. doi: 10.1080/00365529850166860.
Epidermal growth (EGF) and transforming growth factor alpha (TGFalpha) are potent gastric secretory inhibitors, mitogens, and mucosal protectors, but the impact of Helicobacter pylori infection on their mucosal expression and luminal release has not been clarified.
In this study, gene and immunoreactive and immunohistochemical expressions of EGF and TGFalpha were assessed in the gastric mucosa of 15 H. pylori-negative healthy normals, in 22 H. pylori-positive duodenal ulcer patients (DU) and in 24 H. pylori-positive non-ulcer dyspepsia patients (NUD). All studies in DU and NUD patients were repeated after 2 weeks of triple therapy (amoxicillin + clarithromycin + omeprazole) and 4 weeks and 2 years later.
Immunohistochemical expression of EGF and TGFalpha in H. pylori-positive DU and NUD was significantly higher than in H. pylori-negative normals, and this increase persisted at 2 and 4 weeks after therapy but normalized 2 years later. EGF mRNA was detected in the gastric mucosa of H. pylori-positive DU before and at 2 and 4 weeks after H. pylori eradication, but it was not found 2 years after the eradication of H. pylori or in gastric mucosa of H. pylori-negative control subjects. TGFalpha mRNA was detected in the gastric mucosa independently of H. pylori status, with the stronger expression observed in the gastric mucosa of H. pylori-positive DU and NUD before eradication than after this procedure. Plasma gastrin, which was significantly increased in H. pylori-positive DU, normalized already after 2 weeks of triple therapy. The eradication rate as determined by histology after triple therapy reached 86.3% in DU patients and 90.5% in NUD patients. Two years after the eradication the H. pylori reinfection rate was 4.5% among DU patients and 4.2% among NUD. Treatment of DU patients with triple therapy resulted in complete ulcer healing.
表皮生长因子(EGF)和转化生长因子α(TGFα)是强效的胃分泌抑制剂、促细胞分裂剂和黏膜保护剂,但幽门螺杆菌感染对其黏膜表达和腔内释放的影响尚未明确。
在本研究中,对15名幽门螺杆菌阴性的健康正常人、22名幽门螺杆菌阳性的十二指肠溃疡患者(DU)和24名幽门螺杆菌阳性的非溃疡性消化不良患者(NUD)的胃黏膜中EGF和TGFα的基因、免疫反应性及免疫组化表达进行了评估。DU和NUD患者的所有研究在三联疗法(阿莫西林+克拉霉素+奥美拉唑)治疗2周后、4周后及2年后重复进行。
幽门螺杆菌阳性的DU和NUD患者中EGF和TGFα的免疫组化表达显著高于幽门螺杆菌阴性的正常人,且这种增加在治疗后2周和4周持续存在,但在2年后恢复正常。在幽门螺杆菌根除前、根除后2周和4周时,在幽门螺杆菌阳性的DU患者胃黏膜中检测到EGF mRNA,但在幽门螺杆菌根除2年后或幽门螺杆菌阴性对照受试者的胃黏膜中未检测到。TGFα mRNA在胃黏膜中的检测与幽门螺杆菌状态无关,在根除前幽门螺杆菌阳性的DU和NUD患者胃黏膜中的表达强于根除后。幽门螺杆菌阳性的DU患者中显著升高的血浆胃泌素在三联疗法治疗2周后即恢复正常。三联疗法后经组织学检查确定的根除率在DU患者中达到86.3%,在NUD患者中达到90.5%。根除2年后,DU患者中的幽门螺杆菌再感染率为4.5%,NUD患者中为4.2%。三联疗法治疗DU患者导致溃疡完全愈合。
1)幽门螺杆菌慢性感染及由此导致的胃窦炎与血浆胃泌素升高和黏膜细胞增殖增加有关,可能是由于EGF和TGFα表达增强;2)根除幽门螺杆菌导致血浆胃泌素降低,但胃TGFα和EGF含量的增加持续存在,提示它们可能参与溃疡愈合。